QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
NASDAQ:EYPT

EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price & News

$6.13
-0.28 (-4.37%)
(As of 05/18/2023 ET)
Compare
Today's Range
$5.79
$6.76
50-Day Range
$2.28
$9.00
52-Week Range
$2.19
$11.44
Volume
1.14 million shs
Average Volume
674,888 shs
Market Capitalization
$210.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.33

EyePoint Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
434.3% Upside
$32.75 Price Target
Short Interest
Bearish
14.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of EyePoint Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.58) to ($2.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

352nd out of 989 stocks

Analytical Instruments Industry

9th out of 29 stocks


EYPT stock logo

About EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Stock News Headlines

Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Robert W. Baird Remains a Buy on EyePoint Pharmaceuticals (EYPT)
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Robert W. Baird
See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Company Calendar

Last Earnings
3/02/2023
Today
5/18/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYPT
Employees
122
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$32.75
High Stock Price Forecast
$52.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+277.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-102,250,000.00
Net Margins
-257.44%
Pretax Margin
-257.44%

Debt

Sales & Book Value

Annual Sales
$41.40 million
Book Value
$2.29 per share

Miscellaneous

Free Float
30,227,000
Market Cap
$239.07 million
Optionable
Optionable
Beta
1.12

Social Links


Key Executives

  • Nancy Sue Lurker
    Chief Executive Officer & Director
  • Jay S. Duker
    President & Chief Operating Officer
  • George O. Elston
    CFO & Head-Corporate Development
  • Dario A. Paggiarino
    Chief Medical Officer & Senior Vice President
  • Said Saim
    Chief Technology Officer













EYPT Stock - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued 1-year price targets for EyePoint Pharmaceuticals' stock. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they anticipate the company's stock price to reach $32.75 in the next year. This suggests a possible upside of 369.9% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2023?

EyePoint Pharmaceuticals' stock was trading at $3.50 at the beginning of 2023. Since then, EYPT stock has increased by 99.1% and is now trading at $6.97.
View the best growth stocks for 2023 here
.

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our EYPT earnings forecast
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings data on Thursday, March, 2nd. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.02. The business earned $10.53 million during the quarter, compared to analyst estimates of $9.71 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 70.70% and a negative net margin of 257.44%.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals's stock reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (16.85%), Suvretta Capital Management LLC (9.90%), BlackRock Inc. (4.44%), Geode Capital Management LLC (1.40%), Bank of America Corp DE (0.97%) and Essex Investment Management Co. LLC (0.69%).
View institutional ownership trends
.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $6.97.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $239.07 million and generates $41.40 million in revenue each year. The company earns $-102,250,000.00 in net income (profit) each year or ($2.73) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

The company employs 122 workers across the globe.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.

This page (NASDAQ:EYPT) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -